Keros Therapeutics (KROS) Change in Receivables (2021 - 2025)
Keros Therapeutics' (KROS) quarterly Change in Receivables came in at $75000.0 in Q4 2025, down 96.81% YoY from $2.4 million in Q4 2024, and up 100.61% on a QoQ basis from -$12.3 million in Q3 2025.
Keros Therapeutics (KROS) Change in Receivables (2021 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 5 years of Change in Receivables data on file, last reported at $75000.0 in Q4 2025.
- Quarterly Change in Receivables fell 96.81% year-over-year to $75000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $825000.0 (down 68.26% YoY) and the FY2025 annual result came in at $825000.0, down 68.26% from the prior year.
- Change in Receivables improved to $75000.0 in Q4 2025, from -$12.3 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $18.0 million in Q4 2021 to a low of -$18.0 million in Q1 2022.
- A 5-year average of $274384.6 and a median of $83000.0 in 2024 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 17428.92% in 2025, down 3309.38% in 2025.
- Tracing KROS's Change in Receivables over 5 years: stood at $18.0 million in 2021, then slumped by 200.0% to -$18.0 million in 2022, then soared by 100.79% to $143000.0 in 2023, then soared by 1546.15% to $2.4 million in 2024, then slumped by 96.81% to $75000.0 in 2025.
- The last three Change in Receivables figures came in at $75000.0 (Q4 2025), -$12.3 million (Q3 2025), and -$1.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 75,000.00 |
| Dec 31, 2025 | 75,000.00 |
| Sep 30, 2025 | -12.32 Mn |
| Sep 30, 2025 | -12.32 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 384,000.00 |
| Sep 30, 2024 | 384,000.00 |
| Jun 30, 2024 | -222,000.00 |
| Jun 30, 2024 | -222,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Mar 31, 2022 | -18.00 Mn |
| Mar 31, 2022 | -18.00 Mn |